 SALT LAKE CITY, Nov. 22, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc., NASDAQ: MYGN, a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium SABCS that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment. 